Amylyx Pharmaceuticals, Inc. (AMLX) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | -152.09M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $-152.09M | (m) |
| 2026-03-31 | (m) | $-150.11M | (m) |
| 2025-12-31 | (m) | $-144.74M | (m) |
| 2025-09-30 | (m) | $-149.28M | (m) |
| 2025-06-30 | (m) | $-187.60M | (m) |
| 2025-03-31 | (m) | $-218.86M | (m) |
| 2024-12-31 | (m) | $-301.74M | (m) |
| 2024-09-30 | (m) | $-259.47M | (m) |
| 2024-06-30 | (m) | $-165.87M | (m) |
| 2024-03-31 | (m) | $-71.09M | (m) |
| 2023-12-31 | (m) | $49.27M | (m) |
| 2023-09-30 | (m) | $1.84M | (m) |
| 2023-06-30 | (m) | $-72.81M | (m) |
| 2023-03-31 | (m) | $-148.95M | (m) |
| 2022-12-31 | (m) | $-198.38M | (m) |
| 2022-09-30 | (m) | (m) | (m) |
| 2022-06-30 | (m) | (m) | (m) |
| 2022-03-31 | (m) | (m) | (m) |
| 2021-12-31 | (m) | $-87.93M | (m) |
| 2021-09-30 | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| Dyne Therapeutics, Inc. (DYN) | United States | $3.084B | -7.09 |
| Xenon Pharmaceuticals Inc. (XENE) | $3.684B | -14.27 | |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| PRECIGEN, INC. (PGEN) | United States | $2.757B | -12.94 |